Viyash Life Sciences is an API manufacturer based in India. It holds 21 active US drug master files and 9 valid CEPs across a filed portfolio of 26 molecules. Its GMP standing is certified by US FDA and EMA. Its most recent recorded inspection, by US FDA, closed on 25 April 2025 as VAI. Customs aggregates show $1.4M of exports covering 22 molecules to 12 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Hyderabad, India | Not on file |
| Raigad, India | 3003908605 |
| Visakhapatnam, India | 3008652704 |
| Molecule | Regulators | Docs |
|---|---|---|
| Baclofen | EDQM, US FDA | 2 |
| Labetalol | EDQM, US FDA | 2 |
| Lacosamide | EDQM, US FDA | 2 |
| Losartan | EDQM, US FDA | 2 |
| Sertraline Hydrochloride | EDQM | 2 |
| Ticagrelor | EDQM, US FDA | 2 |
| Abacavir | EDQM | 1 |
| Apixaban | US FDA | 1 |
| Clomifene | US FDA | 1 |
| Dapagliflozin | US FDA | 1 |
| Dolutegravir | US FDA | 1 |
| Edoxaban | US FDA | 1 |
| Finerenone | US FDA | 1 |
| Glycopyrronium | US FDA | 1 |
| Lamivudine | US FDA | 1 |
| Lenalidomide | SFDA (Saudi Arabia) | 1 |
| Linagliptin | US FDA | 1 |
| Mavacamten | US FDA | 1 |
| Olmesartan | US FDA | 1 |
| Olmesartan Medoxomil | EDQM | 1 |
| Saxagliptin | SFDA (Saudi Arabia) | 1 |
| Sertraline | US FDA | 1 |
| Tenofovir Disoproxil | US FDA | 1 |
| Vilazodone | US FDA | 1 |
| Viloxazine | US FDA | 1 |
| Vonoprazan | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | None | 2 |
| EMA | None | 2 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $338K | 5 |
| 2025 | Not reported | $1.4M | 12 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Viyash Life Sciences comes back tiered against every other supplier able to file there.
Start for free